DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Celltrion
Celltrion
FTSE Korea 30/18 Capped
Holdings-Report.Pdf
Korea Morning Focus
Remsima
Assessment Report on Extension(S) of Marketing Authorisation
Truxima (Rituximab-Abbs) – New and Expanded Indications
Truxima Prescribing Information
Approved and Pending Biosimilar Applications* *Based on Publicly
CELLTRION Inc. CT-P13 3.5
MSCI Korea Index (USD)
Korea Morning Focus
OPERS Letter in Support of Celltrion's Biologics License Application for A
Morning Focus
INFLECTRA Safely and Effectively
Biosimilar Medicines Authorised Via the EMA
Rituximab - Celltrion Healthcare Pty Ltd - PM- 2017-00695-1-3 - FINAL 13 August 2019
Evidence from Brand Royalty Flows Within Chaebol
INFLECTRA® (Infliximab-Dyyb) Product Monograph Supporting Biosimilarity
Top View
Stoxx® South Korea 200 Index
Summary of Risk Management Plan for Remsima IV/SC and Inflectra IV (Infliximab) This Is a Summary of the Risk Management Plan (RMP) for Remsima IV/SC and Inflectra IV
IKO Ishares MSCI South Korea Capped
Korea Morning Focus
Fact Sheet As of 06/30/2021
Biosimilars in Psoriasis: the Future Or Not?
Rituximab Biosimilar
TIGER KRX Bio K-New Deal ETF(364970
Schroder International Selection Fund Korean Equity
Korea Morning Focus
(“Hospira”) and Celltrion Healthcare Co., Ltd
AQR Emerging Defensive Style Fund September 30, 2020
CT-P10, a Proposed Biosimilar to Rituxan® FDA Advisory Committee Briefing Document
FTSE Publications
Korea Morning Focus
Korea Morning Focus
Index Components (PDF)
Takeda Quarterly Financial Report
Takeda Yakuhin Kogyo Kabushiki Kaisha Takeda Pharmaceutical
Remsma, INN-Infliximab
CT-P13 (Infliximab Biosimilar)
Celltrion Claims a First with Infliximab in US
Annual Securities Report from April 1, 2019 to March 31, 2020
Product Information Infliximab (Rmc) (Remsima)
Truxima, INN-Rituximab
Samsung Biologics (207940 KS) Samsung Bi Ologics
TRUXIMA (Rituximab-Abbs) Is Biosimilar* to RITUXAN® (Rituximab) for the ------WARNINGS and PRECAUTIONS------ Indications Listed